Ivarmacitinib Eased Refractory PCA: Case Report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

  • By

  • Andrea Surnit

  • May 20, 2026

  • 4 min

Share

  • 1

    A 65-year-old man with refractory primary cutaneous amyloidosis showed rapid improvement after off-label treatment with ivarmacitinib.

  • 2

    The patient experienced significant pruritus relief and lesion improvement within one month of starting ivarmacitinib.

  • 3

    Histopathologic examination confirmed the diagnosis of primary cutaneous amyloidosis, showing characteristic amyloid deposits.

  • 4

    Ivarmacitinib, a selective JAK1 inhibitor, may target multiple inflammatory pathways involved in pruritus and T helper 2 inflammation.

  • 5

    The study highlights the potential of ivarmacitinib for treating isolated primary cutaneous amyloidosis, warranting further research.

Original Source(s)

Ivarmacitinib Eased Refractory PCA: Case Report

  • by Andrea Surnit

  • May 20, 2026

Related Content

Earlier Egg Intake Linked to Less Allergy

Population-based data suggest uptake of updated feeding recommendations coincided with modest declines in egg allergy prevalence, particularly among infants with early eczema.

High progesterone may be tied to syringoma

Elevated levels occurred in 29% of women with the condition compared with 6% of controls in a cross-sectional study.

Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials